Open AccessLung adenocarcinoma harboring L858R and T790M mutations in epidermal growth factor receptor, with poor response to gefitinib: A case report
Author(s) -
Yue Feng Wang,
Xianhong Xiang,
Xiaojuan Pei,
Shuhua Li,
Cuilan Tang,
Liantang Wang,
Zunfu Ke
Publication year - 2014
Publication title -
oncology letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.766
H-Index - 54
eISSN - 1792-1082
pISSN - 1792-1074
DOI - 10.3892/ol.2014.2321
Subject(s) - gefitinib , t790m , epidermal growth factor receptor , adenocarcinoma , oncogene , cancer research , lung , cell cycle , molecular medicine , lung cancer , a431 cells , biology , adenocarcinoma of the lung , mutation , epidermal growth factor , oncology , receptor , medicine , cancer , genetics , gene
Lung cancer is the leading cause of mortality among malignant diseases in humans worldwide. During the last decade, molecular targeted therapies for non-small cell lung cancer using first-generation, reversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), including gefitinib, have been shown to be a promising approach for patients harboring activating mutations in EGFR. The current study reports a 77-year-old patient diagnosed with adenocarcinoma harboring L858R and T790M point mutations in the EGFR gene. The patient was treated with gefitinib as the second-line therapy, but no clinical benefit was observed. As the majority of patients with lung cancer receiving EGFR-TKI therapy acquire resistance, repeated biopsies and detection of the EGFR mutation state are beneficial for selecting appropriate treatments.